Zurich Insurance Group Ltd FI Has $68.47 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Zurich Insurance Group Ltd FI cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 473,433 shares of the company's stock after selling 13,261 shares during the quarter. Zurich Insurance Group Ltd FI's holdings in Johnson & Johnson were worth $68,468,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tallon Kerry Patrick acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $290,000. Capital & Planning LLC raised its stake in shares of Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after buying an additional 183 shares in the last quarter. Retirement Wealth Solutions LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $73,000. Canoe Financial LP lifted its stake in shares of Johnson & Johnson by 3.2% in the fourth quarter. Canoe Financial LP now owns 92,626 shares of the company's stock valued at $13,396,000 after purchasing an additional 2,900 shares during the period. Finally, Dominguez Wealth Management Solutions Inc. grew its holdings in shares of Johnson & Johnson by 1.1% in the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 23,707 shares of the company's stock worth $3,429,000 after acquiring an additional 261 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.68 on Thursday, reaching $152.50. 7,528,277 shares of the company were exchanged, compared to its average volume of 7,971,014. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm has a market cap of $366.93 billion, a price-to-earnings ratio of 22.93, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company's 50-day moving average is $155.67 and its two-hundred day moving average is $153.79.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.41%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on JNJ shares. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 16th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.